Olmesartán/Amlodipino/Hidroclorotiazida Stada (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, amlodipine, hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Stada, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑agent therapy is insufficient.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipine/Hydrochlorothiazide is used in the management of hypertension, targeting multiple pathways that control blood pressure. - Hypertension: lowers systolic and diastolic pressure when monotherapy does not achieve target levels. - Resistant hypertension: provides additional control in patients who need more than one class of antihypertensive. - Cardiovascular risk reduction: contributes to lowering the risk of stroke and myocardial infarction associated with high blood pressure.

Adverse reactions may occur with any antihypertensive combination therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Fatigue - Cough - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Electrolyte disturbances (e.g., low potassium) - Acute kidney injury - Angio‑edema - Liver enzyme elevation - Blood cell abnormalities

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: adjust monitoring of kidney function and electrolytes. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte imbalance: watch for potassium and sodium levels. - Pregnancy: avoid use; teratogenic risk is unknown. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original container, protect from moisture and light.

Olmesartan/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Lithium: may increase lithium levels, risking toxicity. - Antidiabetic agents: may enhance hypoglycaemia; monitor glucose. - Alcohol: additive blood‑pressure lowering effect; advise moderation.